scispace - formally typeset
M

Ming-Shyan Huang

Researcher at I-Shou University

Publications -  152
Citations -  4313

Ming-Shyan Huang is an academic researcher from I-Shou University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 35, co-authored 142 publications receiving 3748 citations. Previous affiliations of Ming-Shyan Huang include Kaohsiung Medical University & Kaohsiung Medical University Chung-Ho Memorial Hospital.

Papers
More filters
Journal ArticleDOI

Chinese Food Cooking and Lung Cancer in Women Nonsmokers

TL;DR: A proportion of lung cancer in Taiwanese women nonsmokers may be attributable to the habit of waiting until the cooking oil has been heated to a high temperature before cooking the food.
Journal ArticleDOI

Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer

TL;DR: The expression of FUT8 is up-regulated in nonsmall cell lung cancer (NSCLC) and correlates with tumor metastasis, disease recurrence, and poor survival in patients with NSCLC, and the results of glycoproteomic and microarray analyses show that F UT8 globally modifies surface antigens, receptors, and adhesion molecules and is involved in the regulation of dozens of genes associated with malignancy.
Journal ArticleDOI

Gastro-intestinal metastasis of primary lung carcinoma: Clinical presentations and outcome

TL;DR: Six patients with primary lung cancer demonstrated symptomatic gastro-intestinal metastasis and three patients with gastric metastasis were diagnosed via gastro-endoscopy while one with cecal involvement was diagnosed via colon fiberscopy.
Journal ArticleDOI

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

Martin Schuler, +165 more
- 01 Mar 2016 - 
TL;DR: In this prospective phase III trial, afatinib combined with paclitaxel improved progression-free survival and objective response, compared with single-agent chemotherapy, in patients with NSCLC who were clinically enriched for ErbB dependency having failed platinum-based chemotherapy.